Follow RSS for latest reports on this topicNovoeight (Turoctocog Alfa) - Market Research and Reports

Novoeight (turoctocog alfa) is a recombinant coagulation factor VIII.

The FDA approved Novoeight® for use in adults and children with haemophilia A for:

  • Control and prevention of bleeding
  • Perioperative management
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® has been studied in the guardian™ clinical programme; one of the largest and most comprehensive pre-registration clinical trial programmes in the field of haemophilia therapy with more than 210 severe haemophilia A patients. In the completed trials Novoeight® demonstrated good efficacy in preventing and treating bleeds and had no confirmed inhibitor development, and all patients in the surgery trial were treated effectively. Novoeight® will be launched with the newly introduced prefilled device, MixPro®.

For further information: http://www.novonordisk.com/

BioPortfolio's Easy Ordering System

  1. Search for the report you need from our store
  2. Make online payment with our easy checkout process
  3. Receive PDF report via email

Easy Online Payment or Pro Forma Invoice

We accept the following credit cards...



or can supply a pro-forma invoice if required.

Related Reports:

We found 10 reports that matched your search.

Refine your search, and find more matches, using the form above.

Erythropoietin Stimulating Agent Market: By Type(Epoetin-alfa, Epoetin-beta, Epoetin-omega, Epoetin-delta, Darbepoetin-alfa) Disease Cured(Oncology diseases, Kidney Disorders, Anemia, Neural Disease, Wound healing) & Geography-Forecast (2016-2021) [Report Updated: 10-03-2016]

Erythropoietin is a hormone released the human renal system (kidney) which increases the rate of production of red blood cells in response to falling levels of oxygen in the tissues and helps in the process of erythropoiesis (production of red blood cells). Erythropoietin stimulating agents (EPO) are used to treat people undergone chemotherapy or treatments related to HIV. Globally demand for Eryt...Read More >>>

Published:
2016-03-10

Published by: Industry ARC

Prices Starting From:
$5250

Published:
2016-02-26

Published by: Industry ARC

Prices Starting From:
$5250

Additional Searches

You may also like to search separately for: Novoeight (Turoctocog Alfa)

We Stock...

{STICKYFOOTERMOBILE}